
Global R&D Pipeline
My Favorite
Hot Targets:
CB1R
Back
Total number of drugs
209
Phase II and later clinical stages
12.9%
Involving companies
150
Main therapeutic areas
Other Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CXB-006 | CXB-006 | Small molecule drug | Eye Diseases | Cannabinoid CB1 receptor agonists | PharmaNess Neuroscience | Discontinued | CXB-006 | detail > | |||||||||||||
| INDV-5004 | INDV-5004 | Small molecule drug | Other Diseases | Cannabinoid CB1 receptor antagonists | Indivior Ltd. | Preclinical | INDV-5004 | detail > | |||||||||||||
| Ibipinabant | Ibipinabant | Small molecule drug | Endocrinology and Metabolic Disease | Cannabinoid CB1 receptor antagonists | AbbVie, Inc. | Phase 2/3 | Ibipinabant | detail > | |||||||||||||
| HT-005 Z-Pods | HT-005 Z-Pods | Chemical drugs | Immune System Diseases Skin and Musculoskeletal Diseases Other Diseases | Cannabinoid CB1 receptor agonists Cannabinoid CB2 receptor agonists | Zylö Therapeutic, Inc. | Preclinical | HT-005 Z-Pods | detail > | |||||||||||||
| Dianicline/Rimonabant | Dianicline/Rimonabant | Small molecule drug | Other Diseases | Cannabinoid CB1 receptor antagonists Neuronal acetylcholine receptor; alpha4/beta2 agonists | Sanofi | Discontinued | Dianicline/Rimonabant | detail > | |||||||||||||
| CXB-040 | CXB-040 | Small molecule drug | Eye Diseases | Cannabinoid CB1 receptor agonists | PharmaNess Neuroscience | Discontinued | CXB-040 | detail > | |||||||||||||
| CXB-029 | CXB-029 | Small molecule drug | Nervous System Diseases Endocrinology and Metabolic Disease Eye Diseases Other Diseases | Cannabinoid CB1 receptor antagonists | PharmaNess Neuroscience | Discontinued | CXB-029 | detail > | |||||||||||||
| CCT-717 | CCT-717 | siRNA | Endocrinology and Metabolic Disease | Cannabinoid CB1 receptor antagonists TLE family member 3, transcriptional corepressor inhibitors RNA interference | Canary Cure Therapeutics Inc. | Preclinical | CCT-717 | detail > | |||||||||||||
| CMX-020 | CMX-020 | Small molecule drug | Nervous System Diseases Other Diseases | Cannabinoid CB1 receptor modulators Cannabinoid CB2 receptor modulators | Cytometix, Inc. | Phase 2 | CMX-020 | detail > | |||||||||||||
| CP-741952 | CP-741952 | Small molecule drug | Endocrinology and Metabolic Disease | Cannabinoid CB1 receptor antagonists | Pfizer Inc. | Phase 2 | CP-741952 | detail > |
Total 209 data
1
2
3
4
5
6
...
20
21


